The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 463-474

  Schult, Catrin ^a   Dahlhaus, Meike ^a   Glass, Aenne ^a   Fischer, Kristin ^a   Lange, Sandra ^a   Freund, Mathias ^a   Junghanss, Christian ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Acute lymphoblastic leukemia; Jurcat; MOLT4 cells; mTOR; NVP BEZ235; PI3K; RS4; 11; SEM

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTIMITOTIC AGENT; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE CHECKPOINTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMIDAZOLES; JURKAT CELLS; LEUKEMIA, B-CELL; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84856819520     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. O'Leary M, Krailo M, Anderson JR and Reaman GH: Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol 35: 484-493, 2008.
2. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia: Br J Haematol 150: 389-405, 2010.
3. Gokbuget N and Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol 46: 64-75, 2009.
4. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foa R, Baccarani M and Mandelli F: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Ad. Blood 109: 3676-3678, 2007. (Pubitemid 46641715)
5. Ottmann OG and Pfeifer H: Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program pp. 371-81, 2009.
6. Benekli M, Baumann H and Wetzler M: Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27: 4422-4432, 2009.
7. Mullighan CG: Genomic analysis of acute leukemia. Int J Lab Hematol 31: 384-397, 2009.
8. Kennedy JA and Barabe F: Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia 22: 2029-2040, 2008.
9. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A and McCubrey JA: The emerging role of the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 1803: 991-1002, 2010.
10. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C and Bouscary D: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95: 819-828, 2010.
11. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE and Look AT: High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114: 647-650, 2009.
12. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
13. Huang J and Manning BD: A complex interplay between AKT, TSC2 and the two mTOR complexes. Biochem Soc Trans 37: 217-22, 2009.
14. Meric-Bernstam F and Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2087, 2009.
15. Maira S, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W and Garcia-Echeverria C: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
16. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini P, Maira S, Garcia-Echeverria C, Mercuri M, Picci P and Scotlandi K: NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540, 2010.
17. Baumann P, Mandl-Weber S, Oduncu F and Schmidmaier R: The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315: 485-497, 2009.
18. Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J and Baselga J: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030, 2008.
19. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, Pagliaro P, McCubrey JA and Martelli AM: Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 70: 8097-8107, 2010.
20. Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S, Etro D, Glass A, Fuellen G, Boldt S, Wolkenhauer O, Neri LM, Freund M and Junghanss C: The multikinase inhibitor sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer 10: 560, 2010.
21. Bliss CI: The toxicity of poisons applied jointly. Ann Appl Biol 26: 585-615, 1939.
22. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW and Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684, 2006. (Pubitemid 44848994)
23. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E and Los M: Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10: 13-29, 2007. (Pubitemid 46636381)
24. Bhatt AP, Bhende PM, Sin S, Roy D, Dittmer DP and Damania B: Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115: 4455-4463, 2010.
25. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB and Shimon I: The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the AKT-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol 315: 87-94, 2010.
26. Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, Bradstock KF and Bendall LJ: Potentiating effects of RAD001 (everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113: 3297-3306, 2009.
27. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB and Eng C: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 176: 3062-3072, 2010.
28. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C and Bouscary D: Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/AKT by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111: 379-382, 2008.
29. Shi Y, Yan H, Frost P, Gera J and Lichtenstein A: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4: 1533-1540, 2005. (Pubitemid 41556435)
30. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
31. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ and Sabatini DM: Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to AKT-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-871, 2006. (Pubitemid 44804279)
32. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137, 2006. (Pubitemid 44466632)
33. Baumann P, Hagemeier H, Mandl-Weber S, Franke D and Schmidmaier R: Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by RadOOl. Anticancer Drugs 20: 259-266, 2009.
34. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J and Pandolfi PP: Inhibition of mTORC 1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
35. Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A and Kitanaka C: Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28: 1930-1939, 2010.
36. Nishioka C, Ikezoe T, Yang J and Yokoyama A: Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis: pp. 1-10, 2010.
37. Faber AC, Li D, Song Y, Liang M, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira S, Garcia-Echeverria C, Wong K and Engelman JA: Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 106: 19503-19508, 2009.
38. Zitzmann K, Ruden Jv, Brand S, Goke B, Lichtl J, Spottl G and Auernhammer CJ: Compensatory activation of AKT in response to mTOR and RAF inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295: 100-109, 2010.
39. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira S, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC and Mitsiades CS: Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 69: 5835-5842, 2009.
40. Levis M, Pham R, Smith BD and Small D: In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104: 1145-1150, 2004. (Pubitemid 39038036)
41. Zhou J, Pan M, Xie Z, Loh S, Bi C, Tai Y, Lilly M, Lim Y, Han J, Glaser KB, Albert DH, Davidsen SK and Chen C: Synergistic antileukemic effects between ABT-869 and chemotherapy involve down-regulation of cell cycle-regulated genes and c-MOS-mediated MAPK pathway. Leukemia 22: 138-146, 2008.
42. Janus A, Linke A, Cebula B, Robak T and Smolewski P: Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drugs 20: 693-701, 2009.
43. Huang JJ, Li ZM, Huang Y, Huang Y, Tian Y, He XX, Xiao J and Lin TY: Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. Invest New Drugs 2010.
44. Garza AS, Miller AL, Johnson BH and Thompson EB: Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions. Leuk Res 33: 717-727, 2009.
45. Beesley AH, Palmer M, Ford J, Weiler RE, Cummings AJ, Freitas JR, Firth MJ, Perera KU, de Klerk NH and Kees UR: Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer 95: 1537-1544, 2006. (Pubitemid 44863357)
46. Thompson EB and Johnson BH: Regulation of a distinctive set of genes in glucocorticoid-evoked apoptosis in CEM human lymphoid cells. Recent Prog Horm Res 58: 175-197, 2003. (Pubitemid 37339309)
47. Tissing WJE, den Boer ML, Meijerink JPP, Menezes RX, Swagemakers S, van der Spek PJ, Sallan SE, Armstrong SA and Pieters R: Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 109: 3929-3935, 2007. (Pubitemid 46646638)
48. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR and Armstrong SA: Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10: 331-342, 2006. (Pubitemid 44512194)
49. Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K and Jernberg-Wiklund H: Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103: 3138-3147, 2004. (Pubitemid 38451692)
50. Miller AL, Garza AS, Johnson BH and Thompson EB: Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 7: 3, 2007.